Product Detail
Product NameSAE2/ UBA2 Rabbit mAb
Clone No.JM66-53
Host SpeciesRecombinant Rabbit
Clonality Monoclonal
PurificationProA affinity purified
ApplicationsWB, IP
Species ReactivityHu, Ms, Rt
Immunogen DescRecombinant protein
ConjugateUnconjugated
Other NamesAnthracycline associated resistance ARX antibody
Anthracycline-associated resistance ARX antibody
ARX antibody
FLJ13058 antibody
HRIHFB2115 antibody
SAE 2 antibody
SAE2 antibody
SAE2_HUMAN antibody
SUMO 1 activating enzyme subunit 2 antibody
SUMO activating enzyme subunit 2 antibody
SUMO-activating enzyme subunit 2 antibody
UBA2 antibody
UBA2 ubiquitin activating enzyme E1 homolog antibody
Ubiquitin like 1 activating enzyme E1B antibody
Ubiquitin like modifier activating enzyme 2 antibody
Ubiquitin-like 1-activating enzyme E1B antibody
UBLE1B antibody
Accession NoSwiss-Prot#:Q9UBT2
Uniprot
Q9UBT2
Gene ID
10054;
Calculated MW71 kDa
Formulation1*TBS (pH7.4), 1%BSA, 40%Glycerol. Preservative: 0.05% Sodium Azide.
StorageStore at -20˚C
Application Details
WB: 1:500
IP: 1:10-1:50
Western blot analysis of SAE2/UBA2 on A549 (1) and PC-12 (2) cell lysate using anti-SAE2/UBA2 antibody at 1/500 dilution.
The small ubiquitin-related modifier protein SUMO-1 belongs to the ubiquitin-like protein family, which are synthesized as precursor proteins that undergo processing before conjugation to target proteins. However, SUMO and ubiquitin differ with respect to targeting. Ubiquitination predominantly targets proteins for degradation, whereas sumoylation targets proteins to a variety of cellular processes, including nuclear transport, transcriptional regulation, apoptosis, and protein stability. SUMO-1 utilizes homologues of the E1 and E2 enzymes for conjugation to proteins, which include IkBα, MDM2, p53, PML, and RanGap1. AOS1 is homologous to the N-terminal half of E1 and UBA2 is homologous to the C-terminal half of E1. These proteins form a heterodimer that activates SUMO-1.
If you have published an article using product 49664, please notify us so that we can cite your literature.
Yes
